10% Owner Converts $20.16M Preferred Stock to Common Ahead of Merger
XOMA sits 87% above its 52-week low of $22.29.
Summary
A 10% owner converted $20.16 million in preferred stock to common shares at $4.03 per share, positioning a large block of shares for the company's pending acquisition by Ligand Pharmaceuticals.
Key Events · Ownership and Investor Activity · XOMA
-
Significant Conversion by 10% Owner
Mark N. Lampert and associated entities, a 10% owner, converted Series X Convertible Preferred Stock into 5,003,000 shares of common stock.
-
Substantial Transaction Value
The conversion represents a total value of $20,162,090, executed at a conversion price of $4.03 per share.
-
Pre-Merger Positioning
This conversion occurs ahead of XOMA Royalty Corp's acquisition by Ligand Pharmaceuticals for $39.00 per share, allowing the preferred shareholder to participate in the merger.
Analysis · XOMA · Finance
Mark N. Lampert and affiliated entities, a 10% owner, converted a substantial amount of preferred stock into common shares. This action, valued at over $20 million, is a significant step for the major shareholder to prepare their holdings for the upcoming acquisition of XOMA Royalty Corp by Ligand Pharmaceuticals at $39.00 per share. While a conversion rather than an open-market purchase, its large scale makes it an important pre-merger transaction.
At the time of this filing, XOMA was trading at $41.64 on NASDAQ in the Finance sector, with a market capitalization of approximately $522.2M. The 52-week trading range was $22.29 to $42.81. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.